medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

Liver Transplantation as Cure of Hepatocellular Carcinoma: It is not a Matter of Time, it is a Matter of Tumor Biology

Jochum C, Canbay A

Language: English
References: 12
Page: 326-327
PDF size: 100.40 Kb.


Text Extraction

Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality world-wide. Despite the success in the treatment of hepatitis C and the reduction of hepatitis B in Asia due to immunization programs the incidence of HCC will increase in Europe, North and Southamerica and Asia. This trend is due to the dramatic increase in Non-alcoholic fatty liver disease (NAFLD/ NASH), which is becoming more and more important in the development of HCC. Disease related mortality of HCC is still high, since curative treatment options beside resection and liver transplantation (LT) are lacking. In patients with advanced liver disease and cirrhosis LT is the only curative option. Limitations of treating HCC with LT are the risk of tumor recurrence after LT and the relative organ shortage which causes a competition for organs between patients with HCC and non-malignant end stage liver diseases.


REFERENCES

  1. Seyda Seydel G, Kucukoglu O, Altinbasv A, Demir OO, Yilmaz S, Akkiz H, Otan E, et al. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. Ann Hepatol 2016; 15: 662-72.

  2. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global Trends and Predictions in Hepatocellular Carcinoma Mortality. J Hepatol 2017.

  3. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43.

  4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.

  5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403. doi: 10.1053/jhep.2001.24563. PubMed PMID: 11391528.

  6. Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, Olthoff KM, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 2015; 61: 1643-50.

  7. Palmer WC, Burns J, Croome K, Rosser B, Patel T, Keaveny A, Pungpapong S, et al. Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center. Ann Hepatol 2017; 16.

  8. Bruix J, Sherman M. Diagnosis of Small HCC. Gastroenterology 2005; 129: 1364.

  9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.

  10. Wang P, Meng ZQ, Chen Z, Lin JH, Ping B, Wang LF, Wang BH, et al. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol 2008; 34: 541-6

  11. Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology 2011; 22: 287-305.

  12. Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor- Derived Biomarkers. Dis Markers 2016; 2016: 1427849.




2020     |     www.medigraphic.com